Skip to main content
Premium Trial:

Request an Annual Quote

Trovagene, MD Anderson Partner on Transrenal BRAF Mutation Detection


Trovagene said today that it has entered into a collaboration with the University of Texas MD Anderson Cancer Center to detect transrenal BRAF mutations in the urine of patients with advanced or metastatic cancers.

Under the pact, researchers will use Trovagene's proprietary transrenal DNA detection technology to evaluate BRAF mutation status in urine compared to tissue biopsy. The researchers will also monitor mutation levels in the urine at planned intervals during and after treatment to assess outcomes including response rate; stable disease; progression-free survival; and overall survival. Results from patients who receive therapies such as BRAF inhibitors or MEK inhibitors will be compared to outcomes for patients who receive standard-of-care therapy regardless of mutation status.

The work builds upon a previous collaboration between Trovagene and MD Anderson to detect transrenal KRAS mutations in the urine of patients with pancreatic cancer.

Trovagene said in November that it had completed development of a molecular transrenal assay for detecting KRAS mutations, and expected to transfer the assay to its CLIA lab to offer the test commercially beginning this month. The test will use Bio-Rad's QX100 Droplet Digital PCR system to detect the most prevalent cancer-related KRAS mutations in cell-free nucleic acids from patient urine samples (PCR Insider, 11/29/2012).

The company is also working on assays to detect PIK3CA mutations.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.